27 Results for "

NaV1.1

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "NaV1.1" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-16787
CAS No.: 313254-51-2
Target:  

Sodium Channel

Research Areas:  

Cardiovascular Disease

ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 μM).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147423
CAS No.: 2154406-04-7
Purity:  99.28%
Synonyms: NBI-921352; XEN901
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel NaV1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of NaV1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as NaV1.1 and NaV1.2, and has minimal effect on NaV1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study NaV1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133910
CAS No.: 849000-18-6
Purity:  98.02%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .
loading...
    loading...
Cat. No.: HY-148410A
CAS No.: 2415330-05-9
Purity:  98.25%
Synonyms: STK-001 sodium
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Zorevunersen sodium is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen sodium increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen sodium restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen sodium can be used for research on Dravet syndrome .
loading...
    loading...
Cat. No.: HY-126429
CAS No.: 2332897-85-3
Purity:  99.89%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Nav1.1 activator 1 (compound 4), a highly potent Nav1.1 activator with BBB penetration, increases decay time constant τ of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6 .
loading...
    loading...
Cat. No.: HY-157786
CAS No.: 2230145-14-7
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

XPC-5462 is a selective NaV1.6/1.2 inhibitor, with an IC50 of 0.0103 μM against hNaV1.6, 0.0137 μM against mNaV1.6, and 0.0109 μM against hNaV1.2. XPC-5462 significantly reduces epileptiform discharges. XPC-5462 is applicable for epilepsy-related research .
loading...
    loading...
Cat. No.: HY-157802
CAS No.: 2834106-06-6
Purity:  99.35%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
loading...
    loading...
Cat. No.: HY-125928
CAS No.: 354812-16-1
Purity:  ≥98.0%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

AA43279 is an in gamma-aminobutyric acid (GABA) fast-firing interneurons located activator for Nav1.1 channel (SCN1A) with an EC50 of 9.5 μM. AA43279 enhances specific neuronal firing activity in vitro, and exhibits anticonvulsant activity in rat MEST model .
loading...
    loading...
Cat. No.: HY-122001
CAS No.: 1235406-03-7
Purity:  99.69%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-05186462 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channel, with an IC50 of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .
loading...
    loading...
Cat. No.: HY-148410
CAS No.: 2415330-04-8
Synonyms: STK-001
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Zorevunersen is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen can be used for research on Dravet syndrome .
loading...
    loading...
Cat. No.: HY-178494
CAS No.: 3097995-73-5
Research Areas:  

Neurological Disease

Nav1.7-IN-19 is a potent, selective and orally active Nav1.7 inhibitor with an IC50 of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease .
loading...
    loading...
Cat. No.: HY-P1218B
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
loading...
    loading...
Cat. No.: HY-148410C
Purity:  99.28%
Synonyms: STK-001 negative control
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Zorevunensen (STK-001) negative control is the negative control form of Zorevunensen (HY-148410). Zorevunensen is an antisense oligonucleotide that is intended to increase the level of productive SCN1A mRNA and consequently increase the expression of the sodium channel Nav1.1 protein. Zorevunersen is used for the study of Dravet syndrome .
loading...
    loading...
Cat. No.: HY-P5781
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of NaV1.1 but have no effect on NaV1.7 .
loading...
    loading...
Cat. No.: HY-P1218
CAS No.: 880886-00-0
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
loading...
    loading...
Cat. No.: HY-P5795
Research Areas:  

Neurological Disease

GsAF-I is a potent Nav and hERG1 channels blocker with IC50s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6, Nav1.7 and hERG1, respectively .
loading...
    loading...
Cat. No.: HY-P5783
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

δ-Buthitoxin-Hj2a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 32 nM. δ-Buthitoxin-Hj2a can be used for the Dravet syndrome (DS) research .
loading...
    loading...
Cat. No.: HY-P5784
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

δ-Buthitoxin-Hj1a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 17nM. δ-Buthitoxin-Hj1a can be used for the Dravet syndrome (DS) research .
loading...
    loading...
Cat. No.: HY-P5811
Synonyms: CcoTx1; β-TRTX-cm1a
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Ceratotoxin-1 (CcoTx1), a peptide toxin, is an voltage-gated sodium channel subtypes inhibitor. Ceratotoxin-1 inhibits Nav1.1/β1, Nav1.2/β1, Nav1.4/β1, and Nav1.5/β1 with IC50 of 523 nM, 3 nM, 888 nM, and 323 nM, respectively. Ceratotoxin-1 also inhibits Nav1.8/β1 .
loading...
    loading...
Cat. No.: HY-P1218A
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
loading...
    loading...